Knock-down MALAT1 reduces ox-LDL- induced-inflammation and cell damage of macrophages

doi:10.16352/j.issn.1001-6325.2026.03.0352

Abstract

Abstract: Objective To explore the role and potential mechanism of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in inflammatory response and cell damage of macrophages induced by oxidized low density lipoprotein (ox-LDL). Methods THP-1 cells were induced to differentiate into macrophages by phorbol ester(PMA). Macrophages were co-cultured with ox-LDL to construct a cell injury model. Lipid accumulation was observed by Oil Red O staining microscopy. MALAT1 was knocked down by transfection of shRNA. The experimental group included control group, ox-LDL group, ox-LDL+shNC group and ox-LDL+shMALAT1 group. Total cholesterol and triglyceride in cells were measured. Apoptosis was detected by flow cytometry. The level of IL-6, TNFα and MCP-1 were detected by ELISA. The expression of NLRP3, RIPK1, caspase-8, p65 and SR-A was detected by RT-qPCR and Western blot. Results Compared with the control group, the cell lipid accumulation, total cholesterol and triglyceride contents, cell apoptosis, IL-6, TNFα and MCP-1 levels and the expression of NLRP3, RIPK1, caspase-8, p-p65 and SR-A increased significantly in ox-LDL group(P＜0.05). Compared with ox-LDL group, ox-LDL+shMALAT1 group the contents of total cholesterol and triglyceride, apoptosis, IL-6, TNFα and MCP-1, and the expression of NLRP3, RIPK1, caspase-8, p-p65 and SR-A all significantly decreased(P＜0.05). Conclusions MALAT1 may play an important role in ox-LDL-induced cell injury by regulating NLRP3 inflammatory corpuscles and related signal pathways. Knockdown of MALAT1 can significantly reduce the inflammatory reaction and cell damage induced by ox-LDL, which provides a potential target for the treatment of atherosclerosis.

Key words: atherosclerosis, metastasis-associated lung adenocarcinoma transcript 1(MALAT1), Nod-like receptor protein 3 (NLRP3), inflammation

CLC Number:

R543.5

SONG Ning, LUO Junyi, JI Wei, LI Yanhong, LI Xiaomei, YANG Yining. Knock-down MALAT1 reduces ox-LDL- induced-inflammation and cell damage of macrophages[J]. Basic & Clinical Medicine, 2026, 46(3): 352-358.

References

[1] You FF, Gao J, Gao YN, et al. Association between atherogenic index of plasma and all-cause mortality and specific-mortality: a nationwide population-based cohort study[J]. Cardiovasc Diabetol, 2024, 23: 276. doi:10.1186/S12933-024-02370-4.
[2] Lampsas S, Xenou M, Oikonomou E, et al. Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment[J]. Molecules, 2023, 28: 969. doi: 10.3390/MOLECULES28030969.
[3] Zeng W, Wu D, Sun Y, et al. The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages. Sci Rep. 2021, 29;11:19305. doi: 10.1038/S41598-021-98437-3.
[4] Taghvimi S, Soltani Fard E, Khatami SH, et al. lncRNA HOTAIR and cardiovascular diseases[J]. Funct Integr Genomics, 2024, 24: 165. doi: 10.1007/S10142-024-01444-6.
[5] Blevins HM, Xu Y, Biby S, et al. The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases[J]. Front Aging Neurosci, 2022, 14: 879021. doi: 10.3389/FNAGI.2022.879021.
[6] Lu N, Cheng W, Liu D, et al. NLRP3-mediated inflammation in atherosclerosis and associated therapeutics[J]. Front Cell Dev Biol, 2022, 10: 823387. doi: 10.3389/FCELL.2022.823387.
[7] Bhansali S, Yadav AK, Bakshi C, et al. Interleukin-35 mitigates ox-ldl-induced proatherogenic effects via modulating mirnas associated with coronary artery disease (CAD)[J]. Cardiovasc Drugs Ther, 2023, 37: 667-682.
[8] Bai W, Huo T, Chen X, et al. Sacubitril/valsartan inhibits oxLDLinduced MALAT1 expression, inflammation and apoptosis by suppressing the TLR4/NFkappaB signaling pathway in HUVECs[J]. Mol Med Rep, 2021, 23: 1-8.
[9] Tyrrell D J, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6[J]. Nat Rev Cardiol, 2021, 18: 58-68.
[10] Zeng W, Wu D, Sun Y, et al. The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages[J]. Sci Rep, 2021, 11: 19305. doi:10.1038/S41598-021-98437-3.
[11] Sharma BR, Karki R, Rajesh Y, et al. Immune regulator IRF1 contributes to ZBP1-, AIM2-, RIPK1-, and NLRP12-PANoptosome activation and inflammatory cell death (PANoptosis)[J]. J Biol Chem, 2023, 299: 105141. doi: 10.1016/J.JBC.2023.105141.
[12] Huang X, Liu Y, Liu X, et al. OTUB1 facilitates lipid accumulation in oxLDL-induced THP-1 macrophages by stabilizing scavenger receptor-A[J]. IUBMB Life, 2025, 77: e70012.doi:10.1002/iub.70012.

[1]	REN Leilei, LYU Yulin, WANG Haohua, ZHANG Wanjun, MENG Shu, JIANG Minghong. Aging of NK cells mediates the contradictory phenotype of “high inflammation and weak anti-infection” in dermatomyositis patients [J]. Basic & Clinical Medicine, 2026, 46(3): 345-351.
[2]	HE Ping, WANG Yan. Regulatory role of isthmin-1 in glucose and lipid metabolism and its clinical implications [J]. Basic & Clinical Medicine, 2026, 46(3): 445-449.
[3]	QU Gairu, XI Shibing, ZHANG Zongli, LI Tao. Quercetin inhibits TNF-α-induced inflammation of mouse aortic vascular smooth muscle cell line MOVAS [J]. Basic & Clinical Medicine, 2026, 46(1): 78-84.
[4]	LIU Tingting, GAO Ling, LI Xiaoyan. Research progress on neutrophil extracellular traps in sepsis-induced acute respiratory distress syndrome [J]. Basic & Clinical Medicine, 2026, 46(1): 139-143.
[5]	ZHOU Qi, SUN Xutao, WU Siyu, QU Ying, SONG Yunjia. Role of Sp1 posttranslational modification in atherosclerosis [J]. Basic & Clinical Medicine, 2026, 46(1): 134-138.
[6]	LI Nan, ZHANG Guitao, WANG Bin, FENG Yao, LI Shujuan, ZHOU Yinghua. Correlation between inflammatory response-related indicators and poor outcomes of in-hospital patients with symptomatic stroke [J]. Basic & Clinical Medicine, 2025, 45(8): 1083-1087.
[7]	ZHANG Fangling, ZHANG Yuanfang, ZHANG Li. Dexmedetomidine alleviates nerve injury induced by propofol in neonatal rats [J]. Basic & Clinical Medicine, 2025, 45(5): 644-650.
[8]	LIU Yuhan, WANG Yingying, WANG Yucheng, GUO Lei, JU Rui. Mcart1 knockout enhances the level of macrophage inflammatory response in sepsis model mice [J]. Basic & Clinical Medicine, 2025, 45(5): 616-621.
[9]	HUANG Lian, WEI Hui. PARP9 and PARP14 are involved in microglia-mediated neuroinflammation in Alzheimer′s disease [J]. Basic & Clinical Medicine, 2025, 45(5): 583-588.
[10]	ZHOU Jing, QU Miao. Upregulation of miR-152 inhibits proliferation and migration of human vascular smooth muscle cells induced by ox-LDL [J]. Basic & Clinical Medicine, 2025, 45(4): 486-492.
[11]	LIU Genfeng, NAN Lu, GAO Qin, CHEN Yixuan, ZHANG Jing, YU Peng, YU Shuchun. Dexmedetomidine alleviatesmyocardial ischemia-reperfusion injury in rat models [J]. Basic & Clinical Medicine, 2025, 45(3): 303-309.
[12]	FU Haiwei, GUO Weiwei, SHENG Fen, LIU Donghong. Up-regulation of miR-338-3p alleviatesIL-13-induced injury of human bronchial cell line BEAS-2B [J]. Basic & Clinical Medicine, 2025, 45(3): 346-353.
[13]	YE Min, GUO Xiuying, WANG Danxin, HE Guangliang. Role of anti-aging Klotho gene in inflammatory responses and fibrosis [J]. Basic & Clinical Medicine, 2025, 45(10): 1382-1386.
[14]	MOU Zhongyan, LIU Zhimin, ZHU Shuguang. Atractylenolide Ⅰ mitigates the inflammatory response in a rat model of dextransulfate sodium-induced chronic colitis [J]. Basic & Clinical Medicine, 2025, 45(10): 1326-1332.
[15]	YANG Wen, LI Yong, YANG Zhuoxuan. Small-dose esketamine combined with sufentanil reduces perioperative inflammation in elderly patients with total hip replacement [J]. Basic & Clinical Medicine, 2025, 45(1): 60-64.